2GD drug launched for Covid patients, Defense Minister Rajnath Singh said – ‘a ray of hope’

2GD drug launched for Covid patients, Defense Minister Rajnath Singh said - 'a ray of hope'

Under the first batch of 2 DG (2-deoxy-D-glucose) a new drug affiliated with Defense Research and Development Organization (DRDO) for Coronavirus patients, 10,000 doses on Monday, according to Defense Minister Rajnath Singh (Defense Minister Rajnath Singh) and the Federal Minister of Health released Harshvardan. After three trials, it was approved for emergency use by DCGI on May 1, 2021. In powder form, this drug will be given in a bag that must be dissolved in water. It is able to stop the growth of the virus by visiting infected cells.

Scientists appreciate

On the occasion of the release, the Minister of Defense described the drug as a glimmer of hope. He said, “There is no need to relax and get tired, nor pause, because this wave came for the second time, and there is something in it. More than that, we are not sure. We must take steps very cautiously.” I would like to first honor the scientists who have a major role in preparing this medicine. This medicine has brought a new ray of hope and hope, this medicine is an example of the ability of scientists in our country. He added, “We have taken the oxygen supply system, medicines, intensive care beds, and cold conveyors very seriously. A collective effort has been made to this which results in better.”

The Minister of Defense said, “Up until now we have been talking about DRDO and the private partnership in the defense sector. Today I am really pleased to see such a good result of the DRDO partnership and the private sector in the health sector as well.”

The Minister of Defense gave the information about the drug

For this new drug, the Secretary of Defense said, ‘I was told this DRDO had cured two and a half days before the natural treatment. Dependence on oxygen has also decreased by about 40 percent. Developed as a powder, this medication can be used very easily as an oral rehydration salts solution. At the end of his speech, he appealed to the Minister of Defense to work together. He said, “With the concerted efforts of all of you, this country will be able to face the biggest crises, and it will win in it, and I have full confidence in it.”

Information about this was contained in a tweet published by the Office of the Minister of Defense. It was reported that the first shipment of this drug will be released by the Minister of Defense via video conference at 10:30 in the morning. The drug was developed by the DRDO Institute for Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Doctor Reddy Lab.

DRDO scientists have developed, including Dr. Anant Narayan Bhatt

Last Friday, a DRDO official informed ANI that the first batch of 1,000 doses of 2DG would be released next week and could be given to Covid patients. DRDO officials also noted, “Pharmaceutical manufacturers are working to speed up production for further use. DRDO scientists, including Dr. Anant Narayan Bhatt, have contributed to the manufacture of this drug. A clinical trial of this drug has been conducted with positive results. The experiment revealed that these molecules are Helps in the speedy recovery of patients in the hospital and reduce dependence on excess oxygen.According to Prime Minister Narendra Modi’s request for preparations against the pandemic, the Disease Control and Prevention Organization (DRDO) decided to develop this drug.

An experiment was conducted in 6,11 and 27 hospitals

In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists began working together with the help of CCMB (Center for Cellular and Molecular Biology), Hyderabad and found that these molecules are effective in SARS-CoV-2 and the virus can stop the increase. Based on these results, DCGI permitted its Phase 2 clinical trial in May 2020. Phase 2 trial lasted from May to October of last year and achieved very good results. The experiment was conducted in two parts, in the first time, 6 hospitals were covered, and in the second time, 11 hospitals in the country were covered. In this, this drug was administered to 110 patients and its effective results were demonstrated. In light of this, DCGI has also permitted a third clinical trial that was conducted in 27 hospitals from December 2020 to March 2021 on 220 patients. These hospitals are located in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.

Leave a Reply

Your email address will not be published. Required fields are marked *